Afuco™ Anti-RSV F ADCC Therapeutic Antibody (Palivizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-009 |
| Pricing | Inquiry |
| Host | Human |
| Target | RSV F |
| Species Reactivity | RSV |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |